Expertise in
9
conditions

Huaping L. Dai

Chinese Academy Of Medical Sciences & Peking Union Medical College, 
Beijing, CN 
Expertise in
9
conditions
Chinese Academy Of Medical Sciences & Peking Union Medical College, 
Beijing, CN 

Overview

Huaping Dai practices practicing medicine in Beijing, China.

Dai is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Lung Transplant, and Endoscopy.

They are actively involved in clinical research, co-authoring 338 peer reviewed articles and participating in 2 clinical trials.

Locations

Chinese Academy Of Medical Sciences & Peking Union Medical College, Beijing, China
Other Locations
Shanghai, 200120, China
No. 37, Guoxue Alley, P.R. China, Chengdu, 610041, China
Data, China
Kunming, 650051, China
China
550 Jin Yu Road, P.R. China, Pudong, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
View 1 Less Clinical Trial

338 Total Publications

Measurement of the Λ electric dipole moment with an entangled baryon-antibaryon system.
Measurement of the Λ electric dipole moment with an entangled baryon-antibaryon system.
Journal: Science (New York, N.Y.)
Published: September 03, 2026

Frequently Asked Questions about Huaping L. Dai

Is Huaping L. Dai a top-rated expert for Acute Interstitial Pneumonia?

MediFind is an objective health platform that identifies experts based on real-world data. Huaping L. Dai is classified as an Elite expert for Acute Interstitial Pneumonia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Huaping L. Dai participate in research or clinical trials?

Yes. Huaping L. Dai has published 338 articles and abstracts on conditions like Acute Interstitial Pneumonia. You can view a list of Huaping L. Dai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dai's expertise for a condition
ConditionClose
View All 39 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile